Foundayo's Three Prices: $25, $149, and $50 — Which One Is Yours
Three published numbers, three completely different eligibility routes. Working out which applies to you before you book an appointment.
Bottom line
- Eligible patients with commercial insurance may pay as little as $25/month with a savings card.
- Self-pay patients can access Foundayo starting at $149/month for the lowest dose.
- Eligible Medicare Part D patients gained access at $50/month beginning July 1, 2026.
- The $149 figure is dose-specific — it is the lowest-dose price, and the number most likely to change as you titrate.
Three prices circulate for the same drug. They are not tiers you choose between. They are three separate eligibility routes, and which one applies to you is determined almost entirely by what insurance you have.
The three routes
| Price | Requirement | What to verify |
|---|---|---|
| As little as $25/mo | Commercial insurance + manufacturer savings card | Annual cap, plan exclusions, whether your plan covers the drug at all |
| $50/mo | Medicare Part D, eligible patients, from July 1 2026 | Your specific plan's formulary placement and any prior authorization |
| From $149/mo | Self-pay, lowest dose | Whether this price holds at higher doses |
Route one: commercial insurance and the savings card
The $25 figure is the headline, and it is real for people who qualify. Manufacturer savings programs typically work by covering part of your out-of-pocket cost after your insurance has paid its share.
The two things that most often break this arithmetic:
- Annual caps. Savings programs commonly limit total assistance per calendar year. Hit the cap and your cost reverts, usually mid-year.
- Coverage exclusion. If your plan does not cover the drug for weight management at all, a savings card that reduces your share of a covered cost has nothing to reduce.
Is orforglipron, brand name Foundayo, on my formulary for chronic weight management, at what tier, and does it require prior authorization? A yes to coverage plus a savings card is the $25 scenario. Anything else is not.
Route two: Medicare Part D
Eligible Medicare Part D patients gained access at $50 per month beginning July 1, 2026. Medicare coverage of weight-management drugs has been historically constrained, so this route opening at all is the more significant fact than the specific number.
Part D is not one plan. Formulary placement, tier, and prior authorization requirements vary by the specific plan you are enrolled in, so the $50 figure is a floor available to eligible patients rather than a universal Medicare price.
Route three: self-pay at $149
This is the number most readers should plan against, because it does not depend on insurance behaviour. One qualifier matters enormously: it is the price for the lowest dose.
GLP-1 therapy is titrated. You start low and step up. In the ATTAIN trials, the average of 12.4% weight loss was achieved at the highest dose. If dose-tier pricing applies, the cost you pay in month one is not the cost you pay at maintenance.
Before enrolling anywhere, ask what the self-pay price is at every dose tier, not just the starting one. A program that opens at $149 and steps up materially is a different financial commitment than one that holds flat, and the difference compounds over a year of therapy.
Compare against compounded and marketplace pricing
All providers below are paid partners. Prices shown were recorded at publication and change without notice — always confirm on the provider's own page before you enrol.
Cash-pay marketplace for appointments with clinicians who prescribe FDA-approved brand-name medication only. No compounded product.
Check current pricing Paid partner linkCompounded oral tablets. Lowest verified oral semaglutide price among providers we list without a regulatory flag.
Check current pricing Paid partner linkSublingual semaglutide and oral tirzepatide, compounded.
Check current pricing Paid partner linkHow Foundayo compares on price to compounded oral
At $149 self-pay, Foundayo sits above the cheapest compounded oral semaglutide options and below or near several others. Wellorithm's compounded oral semaglutide runs $147/month and its oral tirzepatide $249/month. MadeMed's sublingual semaglutide runs roughly $99–$169/month.
What you get for the difference is not nothing: FDA review of the finished product, a manufacturer-controlled supply chain, defined dose tiers, and no exposure to the compounding wind-down. On April 30, 2026 the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no remaining clinical need for outsourcing facilities to compound them.
What the price does not tell you
Foundayo carries a boxed warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma, and should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Commonly reported adverse effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair loss. In the trials, gastrointestinal adverse events predominated and discontinuations were higher than with placebo.
Price is one input. It is not the only one, and a drug you discontinue at week six because you could not tolerate it costs more per pound lost than any headline number suggests.
Sources & price verification
- AJMC, “FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity,” including savings card, self-pay, and Medicare Part D pricing.
- US Food and Drug Administration press announcement on approval of Foundayo, April 1, 2026.
- Pharmacy Times, coverage of the ATTAIN-1 and ATTAIN-2 trial results and adverse event profile.
- FDA proposed action on 503B Bulks List status, April 30, 2026.
- Provider pricing recorded from partner program data, September 2026.